HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1 Mottonen T, Hannonen P, Leirisalo-Repo M et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group. Lancet 353(9164), 1568–1573 (1999).
  Medline CASGoogle Scholar
• 2 Van Hees PA, Van Lier HJ, Van Elteren PH et al. Effect of sulphasalazine in patients with active Crohn's disease: a controlled double-blind study. Gut 22(5), 404–409 (1981).
  Medline CASGoogle Scholar
• 3 Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-term maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut 14(12), 923–926 (1973).
  Medline CASGoogle Scholar
• 4 Donovan S, Hawley S, MacCarthy J, Scott DL. Tolerability of enteric-coated sulphasalazine in rheumatoid arthritis: results of a co-operating clinics study. Br. J. Rheumatol. 29(3), 201–204 (1990).
  Medline CASGoogle Scholar
• 5 Peyrière H, Dereure O, Breton H et al. Variability in the clinical pattern of cutaneous side-effects of drugs with systemic symptoms: does a DRESS syndrome really exist? Br. J. Dermatol. 155(2), 422–428 (2006).
  Medline CASGoogle Scholar
• 6 Roujeau JC. Clinical heterogeneity of drug hypersensitivity. Toxicology 209(2), 123–129 (2005).
  Medline CASGoogle Scholar
• 7 Mockenhaupt M. Epidemiology of cutaneous adverse drug reactions. Chem. Immunol. Allergy 97, 1–17 (2012).
  MedlineGoogle Scholar
• 8 Aquino RT, Vergueiro CS, Magliari ME, de Freitas TH. Sulfasalazine-induced DRESS syndrome (drug rash with eosinophilia and systemic symptoms). Sao Paulo Med. J. 126(4), 225–226 (2008).
  MedlineGoogle Scholar
• 9 Bejia I, Ben Hammouda S, Riahi K et al. DRESS syndrome induced by sulphasalazine in rheumatoid arthritis. Joint Bone Spine 73(6), 764–765 (2006).
  MedlineGoogle Scholar
• 10 Michel F, Navellou JC, Ferraud D, Toussirot E, Wendling D. DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis. Joint Bone Spine 72(1), 82–85 (2005).
  MedlineGoogle Scholar
• 11 Bharadwaj M, Illing P, Theodossis A, Purcell AW, Rossjohn J, McCluskey J. Drug hypersensitivity and human leukocyte antigens of the major histocompatibility complex. Annu. Rev. Pharmacol. Toxicol. 52, 401–431 (2012).• Comprehensive review of drug hypersensitivity and HLA.
  Medline CASGoogle Scholar
• 12 Cao ZH, Wei ZY, Zhu QY et al. HLA-B*58:01 allele is associated with augmented risk for both mild and severe cutaneous adverse reactions induced by allopurinol in Han Chinese. Pharmacogenomics 13(10), 1193–1201 (2012). • Confirms the association between HLA-B*58:01 and allopurinol-induced cutaneous adverse reactions in different ethnic groups.
  CASGoogle Scholar
• 13 Roujeau JC, Huynh TN, Bracq C, Guillaume JC, Revuz J, Touraine R. Genetic susceptibility to toxic epidermal necrolysis. Arch. Dermatol. 123(9), 1171–1173 (1987). • One of the earliest studies showing that the immunological gene, HLA, may contribute to drug adverse reactions.
  Medline CASGoogle Scholar
• 14 Bocquet H, Bagot M, Roujeau JC. Drug-induced pseudolymphoma and drug hypersensitivity syndrome (drug rash with eosinophilia and systemic symptoms: DRESS). Semin. Cutan. Med. Surg. 15(4), 250–257 (1996).
  Medline CASGoogle Scholar
• 15 Haldane JB. The estimation and significance of the logarithm of a ratio of frequencies. Ann. Hum. Genet. 20(4), 309–311 (1956).
  Medline CASGoogle Scholar
• 16 RCSB Protein Data Bank. www.pdb.org 
  Google Scholar
• 17 IMGT/HLA database.. www.ebi.ac.uk/ipd/imgt/hla
  Google Scholar
• 18 Eswar N, Webb B, Marti-Renom MA et al. Comparative protein structure modeling using MODELLER. Curr. Protoc. Bioinformatics Chapter 2, Unit 2.9 (2006).
  Google Scholar
• 19 MODELLER program. http://salilab.org/modeller 
  Google Scholar
• 20 Macdonald WA, Purcell AW, Mifsud NA et al. A naturally selected dimorphism within the HLA-B44 supertype alters class I structure, peptide repertoire, and T cell recognition. J. Exp. Med. 198(5), 679–691 (2003).
  Medline CASGoogle Scholar
• 21 Roder G, Blicher T, Justesen S et al. Crystal structures of two peptide–HLA-B*1501 complexes; structural characterization of the HLA-B62 supertype. Acta Crystallogr. D Biol. Crystallogr. 62(Pt 11), 1300–1310 (2006).
  MedlineGoogle Scholar
• 22 Kumar P, Vahedi-Faridi A, Saenger W et al. Structural basis for T cell alloreactivity among three HLA-B14 and HLA-B27 antigens. J. Biol. Chem. 284(43), 29784–29797 (2009).
  Medline CASGoogle Scholar
• 23 Molecular Networks. CORINA. www.molecular-networks.com
  Google Scholar
• 24 Morris GM, Huey R, Lindstrom W et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 30(16), 2785–2791 (2009).
  Medline CASGoogle Scholar
• 25 MGLTools. http://mgltools.scripps.edu
  Google Scholar
• 26 Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 31(2), 455–461 (2010).
  Medline CASGoogle Scholar
• 27 AutoDock Vina. http://vina.scripps.edu
  Google Scholar
• 28 Discover Studio Visualizer 3.5. http://accelrys.com/products/discovery-studio
  Google Scholar
• 29 Tung Y, Escutia B, Blanes M, Navarrro M, Pujol C. [Sulfasalazine-induced hypersensitivity syndrome associated with human herpesvirus 6 reactivation and induction of antiphospholipid syndrome]. Actas Dermosifiliogr. 102(7), 537–540 (2011).
  Medline CASGoogle Scholar
• 30 Augusto JF, Sayegh J, Simon A et al. A case of sulphasalazine-induced DRESS syndrome with delayed acute interstitial nephritis. Nephrol. Dial. Transplant. 24(9), 2940–2942 (2009).
  MedlineGoogle Scholar
• 31 Bahat G, Celik HG, Tufan F et al. Drug rash with eosinophilia and systemic symptoms syndrome induced by sulfasalazine. Joint Bone Spine 77(1), 87–88 (2010).
  MedlineGoogle Scholar
• 32 Maoz KB, Brenner S. Drug rash with eosinophilia and systemic symptoms syndrome: sex and the causative agent. Skinmed 6(6), 271–273 (2007).
  MedlineGoogle Scholar
• 33 Descloux E, Argaud L, Dumortier J, Scoazec JY, Boillot O, Robert D. Favourable issue of a fulminant hepatitis associated with sulfasalazine DRESS syndrome without liver transplantation. Intensive Care Med. 31(12), 1727–1728 (2005).
  MedlineGoogle Scholar
• 34 Mennicke M, Zawodniak A, Keller M et al. Fulminant liver failure after vancomycin in a sulfasalazine-induced DRESS syndrome: fatal recurrence after liver transplantation. Am. J. Transplant. 9(9), 2197–2202 (2009).
  Medline CASGoogle Scholar
• 35 Tohyama M, Yahata Y, Yasukawa M et al. Severe hypersensitivity syndrome due to sulfasalazine associated with reactivation of human herpesvirus 6. Arch. Dermatol. 134(9), 1113–1117 (1998).
  Medline CASGoogle Scholar
• 36 Balci DD, Peker E, Duran N, Dogramaci CA. Sulfasalazine-induced hypersensitivity syndrome in a 15-year-old boy associated with human herpesvirus-6 reactivation. Cutan. Ocul. Toxicol. 28(1), 45–47 (2009).
  MedlineGoogle Scholar
• 37 Yesilova Z, Kantarcioğlu M, Erçin CN et al. Sulfasalazine-induced hypersensitivity: a case report of DRESS syndrome. Turk. J. Gastroenterol. 20(4), 298–299 (2009).
  MedlineGoogle Scholar
• 38 Teo L, Tan E. Sulphasalazine-induced DRESS. Singapore Med. J. 47(3), 237–239 (2006).
  Medline CASGoogle Scholar
• 39 Martin AM, Nolan D, Gaudieri S et al. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc. Natl Acad. Sci. USA 101(12), 4180–4185 (2004). • Demonstrates that HLA-B*57:01 is necessary for abacavir hypersensitivity.
  Medline CASGoogle Scholar
• 40 Saper MA, Bjorkman PJ, Wiley DC. Refined structure of the human histocompatibility antigen HLA-A2 at 2.6 Å resolution. J. Mol. Biol. 219(2), 277–319 (1991).
  Medline CASGoogle Scholar
• 41 Baron JH, Connell AM, Lennard-Jones JE, Avery Jones F. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1(7239), 1094–1096 (1962).
  Medline CASGoogle Scholar
• 42 Knowles SR, Shapiro LE, Shear NH. Anticonvulsant hypersensitivity syndrome. Incidence, prevention and management. Drug Saf. 21, 489–501 (1999).
  Medline CASGoogle Scholar
• 43 Arellano F, Sacristan J. Allopurinol hypersensitivity syndrome: a review. Ann. Pharmacother. 27, 337–343 (1993).
  Medline CASGoogle Scholar
• 44 Macneil M, Haase D, Tremaine R et al. Fever, lymph adenopathy, eosinophilia, lymphocytosis, hepatitis and dermatitis: a severe adverse reaction to minocycline. J. Am. Acad. Dermatol. 36, 347–350 (1997).
  Medline CASGoogle Scholar
• 45 Demoly P, Krope R, Bircher A et al. Drug hypersensitivity questionnaire. Allergy 54, 999–903 (1999).
  Medline CASGoogle Scholar
• 46 Guo Y, Shi L, Hong H, Su Z, Fuscoe J, Ning B. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine. Sci. China Life Sci. 56(2), 119–124 (2013). •• The US FDA and international HIV treatment guidelines recommended HLA-B*57:01 screening prior to abacavir treatment in order to reduce the risk of abacavir-induced hypersensitivity.
  Medline CASGoogle Scholar
• 47 Roujeau JC, Bracq C, Huyn NT, Chaussalet E, Raffin C, Duédari N. HLA phenotypes and bullous cutaneous reactions to drugs. Tissue Antigens 28(4), 251–254 (1986).
  Medline CASGoogle Scholar
• 48 Sullivan JR, Shear NH. The drug hypersensitivity syndrome: what is the pathogenesis? Arch. Dermatol. 137(3), 357–364 (2001).
  Medline CASGoogle Scholar
• 49 Chung WH, Hung S, Hong HS et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428(6982), 486 (2004). •• Demonstrates a strong association between HLA-B*15:02 and Stevens–Johnson syndrome induced by carbamazepine.
  Medline CASGoogle Scholar
• 50 Alfirevic A, Jorgensen AL, Williamson PR, Chadwick DW, Park BK, Pirmohamed M. HLA-B locus in Caucasian patients with carbamazepine hypersensitivity. Pharmacogenomics 7(6), 813–818 (2006).
  CASGoogle Scholar